OncoSec Medical Obtains Allowance of Key Patent Application for Intratumoral Delivery of Plasmid IL-15
January 13 2015 - 6:02AM
Business Wire
OncoSec Medical Inc. (OTCQB: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, announces that the
United States Patent and Trademark Office (USPTO) has allowed
claims covering a method of treating cancerous tumors with
plasmid-encoded IL-15 and electroporation therapy to the tumor
having a field strength of at least 700 V/cm. This announcement
enhances OncoSec’s IP portfolio and provides significant support to
the ongoing expansion of its immuno-oncology pipeline.
"This patent allowance by the USPTO demonstrates our strong
overall commitment to protecting the innovation and commercial
opportunity of our entire intratumoral immunotherapy product
portfolio," said Punit Dhillon, president and chief executive
officer, OncoSec Medical. “IL-15 is regarded as a promising
immunotherapeutic agent, with several other companies evaluating
IL-15 in clinical trials, as well as the National Institutes of
Health. Our delivery approach of electroporation with plasmid IL-12
has demonstrated an excellent safety profile without unwanted
toxicities. This patent allowance provides further evidence of
OncoSec’s role as a leader in the development of intratumoral
immunotherapies.”
IL-15 is a member of the family of IL-2 cytokines. This family
of cytokines activates signaling pathways leading to cellular
activation, proliferation and survival. Specifically, IL-15
exhibits broad activity and induces differentiation and
proliferation of immune cells, such as Natural Killer (NK) cells, T
cells and B cells. Furthermore, IL-15 reverses tolerance to
tumor-associated antigens. Thus, IL-15 potentiates the immune
system, which is important in the immune system’s ability to
recognize and kill the cancer.
The allowed patent application joins a family of two issued U.S.
patents: U.S. 8,026,223, which claims a method of treating
cancerous tumors with plasmid-encoded IL-12 and electroporation
therapy to the tumor; and U.S. 8,802,643, which claims a method of
treating cancerous tumors with plasmid-encoded B7-1, a peripheral
membrane protein found on antigen-presenting cells (APCs), and
electroporation therapy to the tumor, both of which have a field
strength of at least 700 V/cm. This patent family was exclusively
licensed by OncoSec from the University of South Florida.
About OncoSec Medical
OncoSec Medical Inc. is a biopharmaceutical company developing
its investigational ImmunoPulse intratumoral cancer immunotherapy.
OncoSec Medical's core technology is designed to
enhance the local delivery and uptake of DNA IL-12 and
other DNA-based immune-targeting agents. Clinical studies of
ImmunoPulse have demonstrated an acceptable safety profile and
preliminary evidence of anti-tumor activity in the treatment of
various skin cancers, as well as the potential to initiate a
systemic immune response without the systemic toxicities associated
with other treatments. OncoSec's lead program evaluating
ImmunoPulse for the treatment of metastatic melanoma is currently
in Phase 2 development, and is being conducted in collaboration
with several prominent academic medical centers. As the company
continues to evaluate ImmunoPulse in its current indications, it is
also focused on identifying and developing new immune-targeting
agents, investigating additional tumor indications, and evaluating
combination-based immunotherapy approaches. For more information,
please visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
OncoSec Medical Inc.Investor Relations:Jordyn Kopin,
855-662-6732investors@oncosec.comorDian Griesel Int’l.Public
Relations:Laura Radocaj, 212-825-3210lradocaj@dgicomm.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024